Lin Junyi, Li Ying, Sun Jingjing
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68106, U.S.A.
Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska 68106, U.S.A.
Essays Biochem. 2025 May 26. doi: 10.1042/EBC20243001.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by a dense extracellular matrix (ECM) and a uniquely immunosuppressive tumor microenvironment (TME), which together form a formidable barrier that hinders deep drug penetration, limiting the efficacy of conventional therapies and leading to poor patient outcomes. Nanocarrier technology emerges as a promising strategy to improve treatment efficacy in PDAC. Nanocarriers can not only improve drug penetration through their adjustable physicochemical properties but also effectively regulate immune cell function in pancreatic cancer TME and promote anti-tumor immune response. This mini-review discusses the effects of nanocarriers on the immune microenvironment of PDAC, analyzing their mechanisms in modulating immune cells, overcoming ECM barriers, and reshaping the TME.
胰腺导管腺癌（PDAC）是一种侵袭性恶性肿瘤，其特征在于致密的细胞外基质（ECM）和独特的免疫抑制肿瘤微环境（TME），它们共同形成了一个强大的屏障，阻碍药物深度渗透，限制了传统疗法的疗效，并导致患者预后不良。纳米载体技术作为一种有望提高PDAC治疗效果的策略应运而生。纳米载体不仅可以通过其可调节的物理化学性质提高药物渗透，还能有效调节胰腺癌TME中的免疫细胞功能并促进抗肿瘤免疫反应。本综述讨论了纳米载体对PDAC免疫微环境的影响，分析了它们在调节免疫细胞、克服ECM屏障和重塑TME方面的机制。
